Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASKG315 in advanced solid tumors
NCT05554666Phase 1Unknown
- Sponsor
- AskGene Pharma
- Start
- Oct 2022
- Primary completion
- Dec 2023
- Modality
- Prodrugs/Conditional Activator Small Molecules, Fc Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ASKG315 in solid tumor (advanced stage), sponsored by AskGene Pharma. Primary endpoints: Dose limiting toxicities at 21 days and Adverse events at 21 days. Status: unknown.
02
Drugs
ASKG315
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05554666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05554666.